Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.

Abstract: A method of treating an inflammatory disorder in a subject, comprising administering to a subject in need thereof a nucleic acid molecule for inhibiting the expression of Hom-1.

Abstract: A method of treating an inflammatory disorder in a subject, comprising administering to the subject in need thereof a nucleic acid molecule for inhibiting the expression of Hom-1. Specifically, the nucleic acid molecule is an RNAi agent or an antisense morpholino oligonucleotide. Further disclosed is a method of selecting a therapeutic for an inflammatory disorder in a subject, or monitoring the efficacy of a therapeutic for an inflammatory disorder in a subject, comprising detecting the expression level of Hom-1 in an inflamed tissue sample obtained from the subject.

Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.

Abstract: A method of treating a cancer, the method comprising: providing a genetically modified macrophage or monocyte that contains a nucleic acid sequence encoding a Hom-1 polypeptide or a fragment thereof that contains the Hom-1 homeobox domain, wherein the nucleic acid sequence is operably linked to a heterologous promoter and the modified macrophage or monocyte expresses the Hom-1 polypeptide or the fragment thereof; and administering the modified macrophage or monocyte to a subject with a cancer.

Abstract: The invention relates to human homeobox transcription factor VentX and its regulation of differentiation and maturation of human dendritic cells, and related therapeutic and diagnostic compositions and methods of use.

Abstract: The invention relates to human homeobox transcription factor VentX and its regulation of differentiation and maturation of human dendritic cells, and related therapeutic and diagnostic compositions and methods of use.

Abstract: A method of treating a cancer, the method comprising: providing a modified macrophage or monocyte that contains an exogenous nucleic acid sequence encoding a Hom-1 polypeptide or a fragment thereof that contains the Hom-1 homeobox domain, wherein the modified macrophage or monocyte expresses the Hom-1 polypeptide or the fragment thereof; and administering the modified macrophage or monocyte to a subject with a cancer.

Abstract: A method of treating an inflammatory disorder in a subject, comprising administering to the subject in need thereof a nucleic acid molecule for inhibiting the expression of Hom-1. Specifically, the nucleic acid molecule is an RNAi agent or an antisense morpholino oligonucleotide. Further disclosed is a method of selecting a therapeutic for an inflammatory disorder in a subject, or monitoring the efficacy of a therapeutic for an inflammatory disorder in a subject, comprising detecting the expression level of Hom-1 in an inflamed tissue sample obtained from the subject.

Abstract: A method of treating a cancer, the method comprising: providing a genetically modified macrophage or monocyte that contains a nucleic acid sequence encoding a Hom-1 polypeptide or a fragment thereof that contains the Hom-1 homeobox domain, wherein the nucleic acid sequence is operably linked to a heterologous promoter and the modified macrophage or monocyte expresses the Hom-1 polypeptide or the fragment thereof; and administering the modified macrophage or monocyte to a subject with a cancer.

Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.

Abstract: The invention generally relates to human biology discoveries and therapeutic and diagnostic compositions and methods based thereon. More particularly, the invention relates to human homeobox gene VentX and its control of macrophage terminal differentiation and activation, and related therapeutic and diagnostic compositions and methods of use, in particular in connection with inflammatory diseases.

Abstract: Described is a method of expanding hematopoietic stem or progenitor cells. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.

Abstract: The invention relates to human homeobox transcription factor VentX and its regulation of differentiation and maturation of human dendritic cells, and related therapeutic and diagnostic compositions and methods of use.

Abstract: A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.

Abstract: Disclosed are composition and methods for treating development-related disorders. Also disclosed are diagnosis methods, prognosis methods, and drug screening methods.

Abstract: Described is a method of expanding hematopoietic stem or progenitor cells. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.

Abstract: A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.

Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.

Abstract: The invention generally relates to human biology discoveries and therapeutic and diagnostic compositions and methods based thereon. More particularly, the invention relates to human homeobox gene VentX and its control of macrophage terminal differentiation and activation, and related therapeutic and diagnostic compositions and methods of use, in particular in connection with inflammatory diseases.